kraken joining the 39 MiCA licensed CASPs clubpassporting to 450M+ consumers across 30 countriesbbva following their playbook with btc/eth tradingxstocks already doing $1.5M volumeeurope figured out the rulebook first ...

Mesdames et messieurs, bonsoir Vanum et Namastère. Je suis Ramenichetti, je suis indienne et je suis née en Afrique du Sud. Comme mon père et mon grand-père, je suis une entrepreneuse dans l'âme.Aujourd'hui, je vis en France où je dirige une entreprise de conseil en stratégie financière pour les petites et moyennes entreprises. Ce parcours, je le vois comme une voyage de la diaspora indienne. l'une des plus grands diasporats au monde avec plus de 20 millions de personnes dispersées à travers tous les contin ...

Company Overview - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is a biotechnology company focused on developing medicines using a novel anti-inflammatory approach through its proprietary Reactive Aldehyde Species (RASP) platform [1] Lead Asset - The company's lead asset is Reproxalap, which targets Dry Eye Disease (DED) and Allergic Conjunctivitis (AC) [1]

[Musique] Mesdames et messieurs, bonsoir Vanum et Namastère. Je suis Ramenichetti, je suis indienne et je suis née en Afrique du Sud. Comme mon père et mon grand-père, je suis une entrepreneuse dans l'âme.Aujourd'hui, je vis en France où je dirige une entreprise de conseil en stratégie financière pour les petites et moyennes entreprises. Ce parcours, je le vois comme une voyage de la diaspora indienne. l'une des plus grands diasporats au monde avec plus de 20 millions de personnes dispersé à travers tous le ...

And joining me now is Republican Congressman from Ohio, Mike Turner. Thank you so much, Congressman, for being here. I want to get to you on Iran and the latest assessment of the US strikes there.But first, I want to go to you, of course, on the news that's playing out on Capitol Hill. The Senate is voting on amendments to their version of the one big beautiful bill. Where do you stand on that bill.And do you feel comfortable supporting the Senate version of this bill. Well, Misha, I appreciate that. Thank ...

Aldeyra Therapeutics (ALDX) 2025 Conference June 05, 2025 04:20 PM ET Speaker0 Good afternoon, everyone. Welcome to Jefferies Global Healthcare Conference. My name is Clara Dunn, one of the biotech analysts here at Jefferies. So it's my pleasure here to help Aldara's CEO, Doctor. Todd Brady, here with us today for this fireside chat. Welcome. Speaker1 Thank you, Clara. Speaker0 So before we dig into details of your pipeline, maybe it will be helpful for you to give us a quick overview of the company and wha ...

Financial Data and Key Metrics Changes - Net sales for fiscal year 2025 increased by 4% to $20.5 million compared to $19.7 million for fiscal year 2024 [29] - Gross profit increased by 1% year over year to $9.74 million, but gross profit percentage decreased to 47.5% from 50% due to product mix and labor expense reallocations [29][30] - Net income for fiscal year 2025 was $1.2 million or $0.08 per share, down from $1.4 million or $0.09 per share in the prior year [33] Business Line Data and Key Metrics Changes - Integrated coating system sales increased by 28% or $814,000 to $3.7 million, driven by success in the solar energy market [16] - Multi-axis coating systems saw a 6% increase or $603,000 to $10.7 million for the full fiscal year [19] - Medical sales declined by 22% for fiscal year 2025, primarily due to lower demand for stent and balloon coating systems [22] Market Data and Key Metrics Changes - Sales to the alternative clean energy market grew by 64% over the prior fiscal year, significantly impacted by customers transitioning to production scale systems [22] - U.S. and Canadian sales increased by 15% or $1.63 million, representing 61% of total sales compared to 55% in fiscal year 2024 [24] - Latin America sales decreased by 34% or $412,000, while Asian sales declined by 16% or $510,000 due to weak demand from China [25] Company Strategy and Development Direction - The company is focusing on expanding its product offerings in the clean energy sector, medical devices, and semiconductor markets, with a strategic shift towards larger, more complex systems [9][12] - Investments in R&D totaled $2.7 million, aimed at enhancing product capabilities and expanding market reach [27] - The company is optimistic about future growth prospects, particularly in the medical and semiconductor sectors, leveraging its proprietary ultrasonic atomization technology [27][62] Management's Comments on Operating Environment and Future Outlook - Management noted some apprehension in the U.S. clean energy sector regarding order placements, but highlighted strong demand in the EU and Asia [45][46] - The company anticipates continued revenue growth and profitability in the first half of fiscal year 2026, supported by a solid backlog of $8.6 million [13][26] - Visibility into full-year revenue remains limited due to evolving conditions in the clean energy sector and potential tariff impacts [18][20] Other Important Information - The company maintains a strong cash position with cash, cash equivalents, and marketable securities totaling $11.9 million as of February 28, 2025, and has no debt [33] - Capital expenditures for the full year were $496,000, primarily for upgrades to manufacturing and development facilities [34] Q&A Session Summary Question: Clarification on backlog related to Alt Energy - Management confirmed that there are eight systems in backlog from the clean energy sector, all expected to ship in the current fiscal year [40] Question: Visibility on demand and potential pullback - Management acknowledged some apprehension in the U.S. clean energy sector but noted strong demand in other regions [45] Question: Impact of tariffs on business - Management indicated that tariffs have not significantly impacted operations outside of China, with favorable currency exchange rates aiding customer purchases [48] Question: Future growth and order visibility - Management expects to have clearer visibility on full fiscal year performance by the time Q1 earnings are reported [52] Question: Opportunities in medical and semiconductor sectors - Management highlighted strong momentum in both sectors, with a focus on high ASP systems and complex solutions [61][82] Question: Share repurchase program status - Management confirmed an active share repurchase program and stated it is regularly evaluated as part of capital allocation strategy [71]

Financial Data and Key Metrics Changes - Net sales for fiscal year 2025 increased by 4% to $20.5 million compared to $19.7 million for fiscal year 2024 [29] - Gross profit increased by 1% year over year to $9.74 million, but gross profit percentage decreased to 47.5% from 50% in the prior year [29] - Net income for fiscal year 2025 was $1.2 million or $0.08 per share, down from $1.4 million or $0.09 per share in the prior year [33] Business Line Data and Key Metrics Changes - Integrated coating system sales increased by 28% or $814,000 to $3.7 million, driven by success in the clean energy market [15] - Multi-axis coating systems saw sales grow by 6% or $603,000 to $10.7 million for the full fiscal year [18] - Medical sales declined by 22% for fiscal year 2025, primarily due to lower demand for stent and balloon coating systems [21] Market Data and Key Metrics Changes - Sales to the alternative clean energy market grew by 64% over the prior fiscal year [20] - U.S. and Canadian sales increased by 15% or $1.63 million, driven by the delivery of high ASP systems [23] - Latin America sales decreased by 34% or $412,000, influenced by a prior year float glass coating system sale that did not repeat [24] Company Strategy and Development Direction - The company is focusing on expanding into the clean energy sector, with significant growth in advanced solar cells and carbon capture applications [8] - A strategic shift to larger, more complex systems has broadened the addressable market and increased average unit selling prices [7] - The company is optimistic about future demand in the medical and semiconductor markets, leveraging expertise developed in clean energy [61] Management's Comments on Operating Environment and Future Outlook - Management noted some apprehension in the U.S. clean energy sector regarding order placements, but emphasized strong demand in the EU and Asia [45][47] - The company expects continued revenue growth and profitability in the first half of fiscal year 2026, supported by a solid backlog of $8.6 million [12][26] - Visibility into full-year revenue remains limited due to evolving conditions in the clean energy sector and potential tariff impacts [16] Other Important Information - The company invested $2.7 million in R&D for the fiscal year, down from $2.9 million in the prior year [27] - The company maintains a strong cash position with $11.9 million in cash, cash equivalents, and marketable securities, and no debt on the balance sheet [34] Q&A Session Summary Question: Clarification on backlog related to Alt Energy - Management confirmed that there are eight systems in backlog from the clean energy sector, all expected to ship in the current fiscal year [40] Question: Visibility on demand and potential pullback - Management acknowledged some apprehension in the U.S. clean energy sector but noted that the majority of their customers are financially stable [45][46] Question: Opportunities driving backlog in upcoming months - Management highlighted strong momentum in the medical and semiconductor sectors, with ongoing demand for high ASP products [60] Question: Medical market growth and geographical expansion - Management indicated that growth in the medical market is primarily coming from the U.S. and EU, with a shift towards more complex systems [78] Question: Semiconductor market commentary - Management noted that they are offering unique solutions that competitors cannot provide, which is driving progress in the semiconductor sector [83]

证券研究报告|港股公司点评报告 [Table_Date] 2025 年 05 月 13 日 Q1 制造 ASP 一反连续 5 个季度下跌趋势。1）25Q1 制造业收入/归母净利为 13.28/0.64 亿美 元，同比+5.9%/-24.6%，分产品来看运动户外鞋/休闲鞋及运动凉鞋/鞋底、配件及其他收入分别 增长 3.8%/34.3%/-14.9%；分量价来看，产能利用率/鞋履出货量/单价为 91%/0.62 亿双/20.0 美 元，同比+3PCT/+5.3%/+2.5%，价格一反连续 5 个季度下跌趋势增速转正，主要受订单组合影 响 。 25Q1 制造业毛利率 / 经营净利率 / 归母净利率为 17.7%/5.7%/4.8% ， 同 比 下 降 2.6/2.7/2.0PCT，毛利率下降主要由于各个制造厂区的产能负载不均、生产效率欠佳，加上各地 新增人力及薪资上涨，推高工费/收入增加 2.7PCT。净利率降幅低于毛利率主要由于销管研费用 率合计下降 0.4PCT；财务费用率下降 0.7PCT；其他收益占比下降 0.5PC。 零售业务 4 月收入进一步下降。25Q1 宝胜零售业务收入/归母净利 51.07/1.3 ...

华虹半导体 (1347 HK) 港股通 九厂放量有望推动收入稳步增长 | 华泰研究 | | 季报点评 | | --- | --- | --- | | 2025 年 | 5 月 13 日│中国香港 | 半导体 | 1Q25 营收 5.41 亿美元（YoY：+17.6%，QoQ：+0.3%），达到公司指引中 值，主要得益于晶圆出货量增加。付运晶圆 123.1 万片（YoY+20.0%， QoQ+1.5%），产能利用率 102.7%，持续饱满。毛利率 9.2%，同比+2.8pct （产能利用率提升），环比-2.2pct（受新产线折旧影响），符合公司指引的 9%~11%。归母净利润 375 万美元，上季度为净亏损 2520 万美元。展望 Q2，指引营收 5.5-5.7 亿美元（中值环比+3.5%），毛利率 7～9%，主要受 到折旧影响。展望全年：1）看好公司产能持续饱满，12 英寸产能稳步爬坡， 后续有望增厚收入；2）全年价格或稳健，ASP 随着产品组合改善存在上升 空间；3）模拟和电源管理收入稳健增长，受益于关税下国产化趋势加速。 维持华虹的"买入"评级，目标价 43.0 港币。 证券研究报告 目标价 43.0 港 ...